Brooklyn ImmunoTherapeutics Inc. (BTX) saw an uptrend of 6.59% in the recent trading with $9.06 being its most recent. The current price level -88.77% lower than the highest price of $80.67 marked by the stock while trading over the past 52-weeks, whereas it is 160.34% higher than the lowest price of $3.48 the company dropped to over past 52-weeks. The latest news story on BTX appeared in TipRanks under the title “Investing in These 2 Stocks Could Double Your Money, Say Analysts” on Oct-07-21.
Squeezing the time span to 30 day period shows us the stock is currently trading -33.53% below one month high and is +9.82% above of the lowest during that time. Looking into the simple moving average, Brooklyn ImmunoTherapeutics Inc. (BTX)’s stock stands at a SMA-50 of $10.66 while that of 5-day is reading $8.64.
Brooklyn ImmunoTherapeutics Inc. Earnings – What Happened With BTX
Coming around sales and income figures, publically trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
BTX – Brooklyn ImmunoTherapeutics Inc. Stock Earnings Estimates
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 42.45 million. BTX does have institutional investors; and they hold 8.60% of the stock.
Brooklyn ImmunoTherapeutics Inc. – Insider Activity and Holdings
Moreover, the latest SEC filings also revealed that stock came across 1 new insider purchases involving 1 shares. On the other hand, BTX declared 475,000 shares have been sold in 4 insider transactions over the past three months.
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, current ratio recorded by Brooklyn ImmunoTherapeutics Inc. was 0.73 while posting a debt to equity ratio of 0.02. The count was 62.59 for long-term debt to equity ratio.
Brooklyn ImmunoTherapeutics Inc.’s return on equity, or ROE, is -361.00%, compared to the industry average of -68.79% for Healthcare – Biotechnology. Although this indicates that BTX fails to use its equity well, the metric will vary significantly depending on the industry.